| pubmed-article:12855621 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12855621 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:12855621 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:12855621 | lifeskim:mentions | umls-concept:C0014520 | lld:lifeskim |
| pubmed-article:12855621 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:12855621 | lifeskim:mentions | umls-concept:C1443775 | lld:lifeskim |
| pubmed-article:12855621 | lifeskim:mentions | umls-concept:C1709518 | lld:lifeskim |
| pubmed-article:12855621 | lifeskim:mentions | umls-concept:C1135137 | lld:lifeskim |
| pubmed-article:12855621 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:12855621 | pubmed:dateCreated | 2003-7-11 | lld:pubmed |
| pubmed-article:12855621 | pubmed:abstractText | OSI-774 is an inhibitor of the epidermal growth factor receptor tyrosine kinase (EGFR-TK) currently in clinical development. In preclinical models, the antitumor activity of OSI-774 was directly related to its ability to inhibit the EGFR-TK. On the basis of these data, we hypothesized that inhibition of the EGFR-TK will be required for this agent to be effective in the clinic. This study evaluated the pharmacodynamic effects of OSI-774 in normal skin tissues collected from patients treated with the agent in a Phase I study. | lld:pubmed |
| pubmed-article:12855621 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12855621 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12855621 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12855621 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12855621 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12855621 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12855621 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12855621 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12855621 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12855621 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12855621 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12855621 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:12855621 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:12855621 | pubmed:author | pubmed-author:KreisbergJeff... | lld:pubmed |
| pubmed-article:12855621 | pubmed:author | pubmed-author:BrattainMicha... | lld:pubmed |
| pubmed-article:12855621 | pubmed:author | pubmed-author:HidalgoManuel... | lld:pubmed |
| pubmed-article:12855621 | pubmed:author | pubmed-author:HammondLisa... | lld:pubmed |
| pubmed-article:12855621 | pubmed:author | pubmed-author:RowinskyEric... | lld:pubmed |
| pubmed-article:12855621 | pubmed:author | pubmed-author:MalikShazli... | lld:pubmed |
| pubmed-article:12855621 | pubmed:author | pubmed-author:RizzoJineeJ | lld:pubmed |
| pubmed-article:12855621 | pubmed:author | pubmed-author:SiuLillian... | lld:pubmed |
| pubmed-article:12855621 | pubmed:author | pubmed-author:deGraffenried... | lld:pubmed |
| pubmed-article:12855621 | pubmed:author | pubmed-author:BacusSarahS | lld:pubmed |
| pubmed-article:12855621 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12855621 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:12855621 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12855621 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12855621 | pubmed:pagination | 2478-86 | lld:pubmed |
| pubmed-article:12855621 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:12855621 | pubmed:meshHeading | pubmed-meshheading:12855621... | lld:pubmed |
| pubmed-article:12855621 | pubmed:meshHeading | pubmed-meshheading:12855621... | lld:pubmed |
| pubmed-article:12855621 | pubmed:meshHeading | pubmed-meshheading:12855621... | lld:pubmed |
| pubmed-article:12855621 | pubmed:meshHeading | pubmed-meshheading:12855621... | lld:pubmed |
| pubmed-article:12855621 | pubmed:meshHeading | pubmed-meshheading:12855621... | lld:pubmed |
| pubmed-article:12855621 | pubmed:meshHeading | pubmed-meshheading:12855621... | lld:pubmed |
| pubmed-article:12855621 | pubmed:meshHeading | pubmed-meshheading:12855621... | lld:pubmed |
| pubmed-article:12855621 | pubmed:meshHeading | pubmed-meshheading:12855621... | lld:pubmed |
| pubmed-article:12855621 | pubmed:meshHeading | pubmed-meshheading:12855621... | lld:pubmed |
| pubmed-article:12855621 | pubmed:meshHeading | pubmed-meshheading:12855621... | lld:pubmed |
| pubmed-article:12855621 | pubmed:meshHeading | pubmed-meshheading:12855621... | lld:pubmed |
| pubmed-article:12855621 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12855621 | pubmed:articleTitle | Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. | lld:pubmed |
| pubmed-article:12855621 | pubmed:affiliation | The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA. | lld:pubmed |
| pubmed-article:12855621 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12855621 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12855621 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12855621 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12855621 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12855621 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12855621 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12855621 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12855621 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12855621 | lld:pubmed |
